Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.47 |
| ▸ | FPR2 | P25090 | 4/20 | 0.47 |
| ▸ | FNTA | P49354 | 11/20 | 0.45 |
| ▸ | FNTB | P49356 | 11/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 9/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83021 | 0.87 | NPY1R (0.46) | FPR1FPR2FNTAFNTBPGGT1B | |
| SCHEMBL18106731 | 0.85 | FNTA (0.54) | FPR1FPR2FNTAFNTBPGGT1B | |
| SCHEMBL29212842 | 0.85 | FPR1 (0.49) | FPR1FPR2FNTAFNTBPGGT1B | |
| SCHEMBL856024 | 0.85 | FNTA (0.54) | FPR1FPR2FNTAFNTBPGGT1B | |
| SCHEMBL1695337 | 0.84 | FOLH1 (0.57) | FPR1FPR2FNTAFNTBNPY1R | |
| SCHEMBL1695336 | 0.84 | FOLH1 (0.57) | FPR1FPR2FNTAFNTBNPY1R | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4592799 | 0.84 | FPR1 (0.61) | FPR1FPR2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39529 | 0.84 | FPR1 (0.61) | FPR1FPR2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL9903983 | 0.84 | FPR1 (0.61) | FPR1FPR2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL17202476 | 0.84 | FPR1 (0.61) | FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | FPR1 454/4885FPR2 513/4885FNTA 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.